More on AXK
Data
Financials
News
Click line-items for a historical chart and %
| OptiChem(R) revenues | 22K |
| Technical development fees | |
| Product Licensing Fees | |
| Qualified Therapeutic Discovery Grant | |
| Total Revenues | 24K |
| Research and development | 7.53M |
| General and administrative | 9.31M |
| Amortization | 3K |
| Marketing and sales | |
| Depreciation | 598K |
| Total costs and expenses | 17.44M |
| Income (Loss) from operations | -17.42M |
| Interest and dividend income | 117K |
| Unrealized gain (loss) on investments | |
| Gain on sale of equipment | |
| Total other income | |
| Net Income (loss) | -17.3M |
| Basic and diluted net loss per share | -0.34 |
| Weighted average shares outstanding | 51.24M |
Entities mentioned with AXK
- Earnings | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- EMS Technologies/Honeywell | View Related Stories »
- FDIC | View Related Stories »
- Citi | View Related Stories »
- Credit Suisse | View Related Stories »
- ThinkEquity | View Related Stories »
- Deutsche Bank | View Related Stories »
- Show More...
